1483 results for Leukemia
Refine Your Search
What's on the Horizon for Chronic Myeloid Leukemia?
[Click here to enlarge.] Topics Covered We invite you to learn more about: Audio Replay …
What’s on the Horizon for Chronic Lymphocytic Leukemia?
Topics Covered We invite you to learn more about: Diagnosing chronic lymphocytic leukemia (CLL) New and emerging therapies Supportive care and …
The Leukemia & Lymphoma Society Honors Dr. Sherie Morrison
On Wednesday, November , The Leukemia & Lymphoma Society California Southland Chapter held a dinner to honor Dr. Sherie Morrison, a preeminent researc…
LLS PedAL: Precision Medicine for Children with Leukemia
As part of The LLS Children’s Initiative, LLS is working with a team of renowned pediatric oncologists to lay the groundwork for a global precision me…
The Leukemia & Lymphoma Society Joins CancerX Inaugural Project
The Leukemia & Lymphoma Society (LLS) has joined on as a proud partner of CancerX’s inaugural project, “Advancing Digital Innovation to Improve Equit…
News Release
Advances in Treatment for Chronic Lymphocytic Leukemia (CLL)
Topics Covered We invite you to learn more about: Current and emerging therapies for CLL Managing side effects to promote a better quality of lif…
SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia
The goal of our work is to use a “bench to bedside and back” approach to develop new treatments for patients with relapsed/refractory AML. Through gen…
Storyectomy*
A storytelling event using truth and comedy to support blood cancer survivors and caregivers. Explore the stories and videos.
Blog
The hills I have climbed
Shock. Grief. Needing support from your community. Costs of medication, doctors’ appointments, treatment. These are all common with a blood ca…
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
SAN DIEGO, December , – Kura Oncology, Inc. (NASDAQ: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines fo…
News Release
Breaking Down Barriers in Blood Cancer Care
When I meet blood cancer survivors and their families, they often share their personal stories with me. Sometimes they talk about the relief of findin…
“People Just Didn’t Get It”: Treating Young Adults with Cancer
Think of spring break: warm sunny skies, a refreshing drink, and hopefully, a feeling of freedom. Allison Rosenthal was dreaming of all of it in her …
Where Blood Cancer Meets Nature: Why This Scholarship Recipient Is Saving the Earth
When we think about the future, a lot can feel uncertain—especially as a teenager or young adult (AYA) with blood cancer. We get it. The AYA crowd f…
#ASH18: Beating AML
Sunday marked a significant milestone for The Leukemia & Lymphoma Society (LLS) and the patients we help. Here at the 60th American Society of Hematol…
NBA Rookie Honors Late Coach by Donating Car to LLS
Thanks to Towns, The Leukemia & Lymphoma Society (LLS) will be getting a brand new Kia!The NBA awarded the - Kia NBA Rookie of the Year Award to Tow…
LLS Races to Get Faster Care for Children with Cancer with Accelerating Kids’ Access to Care Act
The Leukemia & Lymphoma Society is dedicated to helping find cures for pediatric blood cancers. But we—and pediatric families across the country—know …
Exercise for blood cancer patients
Table of contents:Exercise for Blood Cancer PatientsWhy is being physically active important for blood cancer patients?Goals of an exercise progra…
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphom…
Volunteers: The Engine Powering LLS’s Mission
I was always aware that volunteers with The Leukemia & Lymphoma Society (LLS) drive impact for blood cancer patients and families. But it wasn’t until…
Lower Dose Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
regimens are the standard of care for many patients with acute myeloid leukemia (AML) and are highly active therapeutic strategies for this challengin…
Mechanisms of oncogenic transcription in NPM1-mutant myeloid leukemia
NPM1-mutated leukemia is the most common AML in adult and characterized by upregulations of HOXA/B genes and MEIS1. Given the importance of oncogenic …
Functionalizing novel PHIP variants in ancestry-specific acute myeloid leukemia
AML risk stratification established by previous studies do not reflect survival outcomes observed in Black patients. Exome sequencing of Black AML pa…
Advancing the therapeutic landscape for Chronic Myelomonocytic Leukemia (CMML)
CMML is a universally lethal blood cancer characterized by increased monocytes (a type of white blood cell) in the peripheral blood and abnormal appea…